2024
Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront costReal-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study
Huntington S, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, De Nigris E. Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study. Leukemia & Lymphoma 2024, 65: 932-942. PMID: 38696747, DOI: 10.1080/10428194.2024.2331631.Peer-Reviewed Original ResearchSequential targeted therapyLymphocytic lymphomaTherapy useB-cell lymphoma 2 inhibitorChronic lymphocytic leukemia/small lymphocytic lymphomaBruton tyrosine kinase inhibitorTargeted therapy useSmall lymphocytic lymphomaChronic lymphocytic leukemiaTyrosine kinase inhibitorsProportion of patientsClaims-based studyFirst-lineLymphocytic leukemiaTargeted therapyClinical outcomesB cellsKinase inhibitorsTreatment sequenceReal-world patternsTherapyCLL/SLLBTKiCD20Lymphoma
2019
Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer
Giri S, Huntington SF. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer. JAMA Oncology 2019, 5: 1066-1066. PMID: 31095252, DOI: 10.1001/jamaoncol.2019.1088.Peer-Reviewed Original Research
2018
Costs of relapsed diffuse large B-cell lymphoma among Medicare patients
Huntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59: 2880-2887. PMID: 29936866, DOI: 10.1080/10428194.2018.1459613.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCost of IllnessFemaleHealth Care CostsHospitalizationHumansInsurance Claim ReviewLymphoma, Large B-Cell, DiffuseMaleMedicareNeoplasm Recurrence, LocalRetrospective StudiesTreatment OutcomeUnited StatesConceptsDiffuse large B-cell lymphomaHealth care costsLarge B-cell lymphomaFirst-line treatmentB-cell lymphomaCare costsHealth care expendituresCare expendituresHigher health care costsOffice visit costsSecond-line therapyFirst-line therapyHigher medical costsLikelihood of relapseRelapsed cohortMedicare patientsMedicare claimsMedical costsVisit costsPropensity scoreOlder adultsPatientsLymphomaTherapyTreatmentCounseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer Journal 2018, 8: 55. PMID: 29891916, PMCID: PMC5995881, DOI: 10.1038/s41408-018-0081-8.Peer-Reviewed Original ResearchThe changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013
Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF. The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. American Journal Of Hematology 2018, 93: 874-881. PMID: 29659047, DOI: 10.1002/ajh.25116.Peer-Reviewed Original ResearchConceptsPosttransplant lymphoproliferative disorderEBV serostatusMonomorphic histologyPTLD casesLymphoproliferative disordersMonomorphic posttransplant lymphoproliferative disorderPolymorphic posttransplant lymphoproliferative disordersTime of transplantTacrolimus useImmunosuppressive regimensImmunosuppressive therapyTransplant patientsTransplant recipientsClinical managementDifferent prognosisOPTN databaseOrgan transplantationDifferent malignanciesHistologyLate occurrenceSerostatusTransplantPotential causesTherapyDisorders
2017
Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation
Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2017, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.Peer-Reviewed Original Research
2015
Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma
Huntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 2015, 56: 2579-2584. PMID: 25629993, DOI: 10.3109/10428194.2015.1007506.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, Murine-DerivedAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleFluorodeoxyglucose F18HumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedOutcome Assessment, Health CarePositron-Emission TomographyPrednisoneProportional Hazards ModelsRemission InductionRetrospective StudiesRituximabTomography, X-Ray ComputedVincristineYoung AdultConceptsDiffuse large B-cell lymphomaFluorodeoxyglucose positron emission tomography-computed tomographyPositron emission tomography-computed tomographyEmission tomography-computed tomographyLarge B-cell lymphomaFirst-line therapyMajority of patientsTomography-computed tomographyB-cell lymphomaI-PETPET/CTFrontline therapyClinical utilityInterim PET/CTTreatment PET/CTProgression-free survivalEnd of treatmentLittle clinical utilityPost-treatment assessmentRetrospective studyPretreatment stagingMultivariable modelingPatientsTreatment imagingTherapy
2014
Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL).
Huntington S, Nasta S, Schuster S, Doshi J, Svoboda J. Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL). Journal Of Clinical Oncology 2014, 32: 8549-8549. DOI: 10.1200/jco.2014.32.15_suppl.8549.Peer-Reviewed Original Research